SG11201607213QA - Methods and compositions for increasing a t-effector cell to regulatory t cell ratio - Google Patents
Methods and compositions for increasing a t-effector cell to regulatory t cell ratioInfo
- Publication number
- SG11201607213QA SG11201607213QA SG11201607213QA SG11201607213QA SG11201607213QA SG 11201607213Q A SG11201607213Q A SG 11201607213QA SG 11201607213Q A SG11201607213Q A SG 11201607213QA SG 11201607213Q A SG11201607213Q A SG 11201607213QA SG 11201607213Q A SG11201607213Q A SG 11201607213QA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- regulatory
- compositions
- increasing
- methods
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title 1
- 239000012636 effector Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461948453P | 2014-03-05 | 2014-03-05 | |
PCT/US2015/018915 WO2015134722A2 (en) | 2014-03-05 | 2015-03-05 | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607213QA true SG11201607213QA (en) | 2016-09-29 |
Family
ID=54055997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607213QA SG11201607213QA (en) | 2014-03-05 | 2015-03-05 | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170080064A1 (en) |
EP (1) | EP3113794A4 (en) |
JP (1) | JP2017508797A (en) |
KR (1) | KR20160132033A (en) |
CN (1) | CN106413745A (en) |
AU (1) | AU2015227163A1 (en) |
BR (1) | BR112016020364A2 (en) |
CA (1) | CA2941405A1 (en) |
IL (1) | IL247458A0 (en) |
MA (1) | MA39717A (en) |
MX (1) | MX2016011537A (en) |
RU (1) | RU2016138601A (en) |
SG (1) | SG11201607213QA (en) |
WO (1) | WO2015134722A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
EP3332804A1 (en) | 2011-03-11 | 2018-06-13 | Advaxis, Inc. | Listeria-based adjuvants |
CN104411327A (en) | 2012-03-12 | 2015-03-11 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
AU2015219161A1 (en) | 2014-02-18 | 2016-09-29 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
JP7009061B2 (en) | 2014-04-24 | 2022-01-25 | アドバクシス, インコーポレイテッド | Recombinant Listeria vaccine strain and method for producing it |
EP3207162A4 (en) * | 2014-10-14 | 2018-07-04 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
TW201725050A (en) * | 2015-10-09 | 2017-07-16 | 創祐生技股份有限公司 臺北市南港區園區街3號17樓 Wr-09 | Anti-cancer vaccine combination |
JP7114477B2 (en) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | Identification, production and use of neoantigens |
JP7197481B2 (en) | 2016-11-30 | 2022-12-27 | アドバクシス, インコーポレイテッド | Immunogenic compositions targeting recurrent cancer mutations and methods of their use |
WO2019003159A1 (en) * | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies for treating fibrosis |
JP7097438B2 (en) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | Genetically engineered immunostimulatory bacterial strains and their use |
MX2020003100A (en) | 2017-09-19 | 2020-08-20 | Advaxis Inc | COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR <i>LISTERIA </i>STRAINS. |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
CN110408634B (en) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | Non-integrated listeria vaccine and anti-tumor immune response method |
CN112673092B (en) * | 2018-07-11 | 2024-03-29 | 阿克蒂姆治疗有限公司 | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662396B2 (en) * | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
WO2006017856A2 (en) * | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
PT2403935T (en) * | 2009-03-04 | 2017-09-22 | Univ Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
CN104411327A (en) * | 2012-03-12 | 2015-03-11 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
BR112016019534A2 (en) * | 2014-02-25 | 2017-10-24 | Advaxis Inc | methods of treating tumor growth and eliciting an enhanced immune response against tumor growth |
-
2015
- 2015-03-05 MX MX2016011537A patent/MX2016011537A/en unknown
- 2015-03-05 RU RU2016138601A patent/RU2016138601A/en not_active Application Discontinuation
- 2015-03-05 MA MA039717A patent/MA39717A/en unknown
- 2015-03-05 US US15/123,468 patent/US20170080064A1/en not_active Abandoned
- 2015-03-05 CA CA2941405A patent/CA2941405A1/en not_active Abandoned
- 2015-03-05 JP JP2016573685A patent/JP2017508797A/en active Pending
- 2015-03-05 EP EP15758226.3A patent/EP3113794A4/en not_active Withdrawn
- 2015-03-05 WO PCT/US2015/018915 patent/WO2015134722A2/en active Application Filing
- 2015-03-05 CN CN201580011943.7A patent/CN106413745A/en active Pending
- 2015-03-05 KR KR1020167025525A patent/KR20160132033A/en unknown
- 2015-03-05 AU AU2015227163A patent/AU2015227163A1/en not_active Abandoned
- 2015-03-05 BR BR112016020364-0A patent/BR112016020364A2/en not_active Application Discontinuation
- 2015-03-05 SG SG11201607213QA patent/SG11201607213QA/en unknown
-
2016
- 2016-08-24 IL IL247458A patent/IL247458A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016011537A (en) | 2017-05-01 |
CA2941405A1 (en) | 2015-09-11 |
MA39717A (en) | 2017-01-11 |
AU2015227163A1 (en) | 2016-10-20 |
KR20160132033A (en) | 2016-11-16 |
WO2015134722A3 (en) | 2015-10-29 |
WO2015134722A2 (en) | 2015-09-11 |
EP3113794A4 (en) | 2017-09-06 |
JP2017508797A (en) | 2017-03-30 |
CN106413745A (en) | 2017-02-15 |
US20170080064A1 (en) | 2017-03-23 |
EP3113794A2 (en) | 2017-01-11 |
IL247458A0 (en) | 2016-11-30 |
BR112016020364A2 (en) | 2018-01-16 |
RU2016138601A (en) | 2018-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247458A0 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
ZA201901336B (en) | Improved t cell compositions | |
IL274903A (en) | Cell | |
HK1243333A1 (en) | Methods and compositions for modified t cells | |
IL242273B (en) | Methods and compositions for enhancing cd4+ regulatory t cells | |
SG11201609059TA (en) | Fuel compositions | |
SG10202000644TA (en) | Improved Stem Cell Composition | |
SG11201606035RA (en) | Fuel compositions | |
SG11201702475VA (en) | Methods and compositions for modulating th-gm cell function | |
IL247890A0 (en) | Methods relating to pluripotent cells | |
HUE042287T2 (en) | Lithium-sulphur cell | |
GB201413781D0 (en) | Fuel cell | |
GB2522473B (en) | Improvements to windposts | |
GB201411625D0 (en) | Fuel cell | |
GB2520781B (en) | Improvements to hydro-turbines | |
GB201416750D0 (en) | Cell preparation | |
AU356621S (en) | Utility can | |
GB201411268D0 (en) | Improvements to magflow meters | |
GB201406459D0 (en) | Improvements to gas turbines | |
GB201405489D0 (en) | Able to go | |
GB201414608D0 (en) | Improvements to structure | |
GB201401825D0 (en) | Fuel compositions | |
GB201410934D0 (en) | T cell |